2; (v) the 2.7 kb fragment

and flanking kanamycin resistance Rucaparib order cassette was PCR amplified using primers 5′BB0620mutF3 and pBSV2 R1; (vi) the resulting 4.3 kb amplicon was TA cloned into pGEM T-Easy to create pBB0620.3A or B (based on orientation of the PCR product insertion); (vii) a pBB0620.3B clone was identified by restriction digest in which the 3′ end of the kanamycin resistance cassette was adjacent to the SacII restriction site in the pGEM T-Easy vector; (viii) the 5′ end of bb0620 and flanking DNA was amplified using primers 3′BB0620mutF2 (SacII) and 3′BB0620mutR2 (AatII) and TA cloned into pCR2.1 to create pBB0620.4; (ix) pBB0620.3B and pBB0620.4 were digested with SacII and AatII and separated by gel electrophoresis; (x) the 1.7 kb fragment from pBB0620.4 was gel extracted and cloned into the gel extracted fragment from pBB0620.3B to create the final construct, pBB0620.5. In summary, 81 bp near the 5′ end of bb0620 were deleted and the kanamycin cassette under control of the B. burgdorferi P flgB promoter (from pBSV2) was inserted in the opposite orientation. All plasmid constructs described above were confirmed by restriction digestion and/or sequence analysis. Plasmids pBB0002.7 and pBB0620.5 were used to generate deletion/insertion mutations in B31-A. Specifically, plasmids were concentrated to greater than 1

μg μl-1 and 10 μg of each plasmid was introduced into separate competent B31-A preparations by electroporation. Cells from each transformation reaction were resuspended in Talazoparib research buy 10 ml of BSK-II containing 20 μg ml-1 phosphomycin, 50 μg ml-1 rifampicin and 2.5 μg ml-1 amphotericin B (Antibiotic Mixture for Borrelia 100×; Sigma-Aldrich; St. Louis, MO), and allowed to recover overnight (18-24 h) prior to plating. Cells were plated on BSK-II containing either 100 μg ml-1 streptomycin (pBB0002.7) or 340 μg ml-1 kanamycin (pBB0620.5) according to the protocol of Samuels et al [39]. Antibiotic resistant colonies appearing 10-14 d after

plating were transferred to liquid BSK-II and cell lysates were screened by PCR using primers flanking the antibiotic insertion site. One clone for each mutation was chosen for growth experiments. The bb0002 mutant was designated RR04, and the bb0620 Etofibrate mutant was designated RR53. Mutations in RR04 and RR53 were confirmed by PCR amplification of genomic DNA using primers flanking the antibiotic insertion site [Additional file 1 and Additional file 2], and DNA sequencing confirmed insertion of the antibiotic resistance gene. To generate the bb0002/bb0620 double mutant, competent RR04 cells were transformed with 10 μg of pBB0620.5. Cells were resuspended in BSK-II and allowed to recover overnight prior to plating on BSK-II containing 100 μg ml-1 streptomycin and 340 μg ml-1 kanamycin. PCR was used to screen the transformants and a clone containing mutations in both genes was designated RR60.